180 Life Sciences Corp.
ATNF
$0.8599
-$0.0011-0.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -33.00% | -76.31% | -55.66% | -61.17% | -70.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.17% | -72.33% | -49.86% | -56.44% | -74.25% |
| Operating Income | 3.17% | 72.33% | 49.86% | 56.44% | 74.25% |
| Income Before Tax | -271.05% | 93.37% | 100.32% | 77.54% | 94.57% |
| Income Tax Expenses | -6,627.27% | -- | -- | -- | 99.53% |
| Earnings from Continuing Operations | -248.26% | 91.85% | 100.32% | 77.54% | 94.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -248.26% | 91.85% | 100.32% | 77.54% | 94.36% |
| EBIT | 3.17% | 72.33% | 49.86% | 56.44% | 74.25% |
| EBITDA | 2.65% | 72.47% | 50.12% | 56.74% | 74.48% |
| EPS Basic | -455.81% | 96.52% | 100.10% | 93.06% | 98.94% |
| Normalized Basic EPS | -17.57% | 89.49% | 98.82% | 93.06% | 94.20% |
| EPS Diluted | -454.80% | 96.52% | 100.07% | 93.04% | 98.93% |
| Normalized Diluted EPS | -17.57% | 89.49% | 98.82% | 93.06% | 94.20% |
| Average Basic Shares Outstanding | 80.11% | 134.31% | 233.85% | 223.68% | 430.58% |
| Average Diluted Shares Outstanding | 80.11% | 134.31% | 233.85% | 223.68% | 430.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |